Product image of Midnight/Tikun (Dronabinol, Cannabidiol) supplied by GNH India

Midnight/Tikun

Active Ingredient:
Dronabinol, Cannabidiol
Origin:
EU

Midnight/Tikun (Dronabinol, Cannabidiol)

Dronabinol and Cannabidiol, the active ingredients in Midnight/Tikun, are cannabinoids presented as an inhalation form for inhalation use. They treat nausea and vomiting associated with chemotherapy, stimulate appetite in patients with AIDS or cachexia, and provide analgesic effects for chronic pain.\n\nGNH India supplies Midnight/Tikun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Manufacturer / TM Owner

Tikun Olam Greece S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Midnight/Tikun acts on the endocannabinoid system to address several serious conditions.\n\n- Chemotherapy‑induced nausea and vomiting: reduces frequency and severity of episodes.\n- AIDS‑related cachexia: stimulates appetite and supports weight gain.\n- Certain seizure disorders: decreases seizure frequency in eligible patients.\n- Chronic pain: provides analgesic relief where conventional therapies are insufficient.

How It Works

  • Dronabinol and cannabidiol act as partial agonists at cannabinoid receptors CB1 and CB2. Activation of CB1 modulates neurotransmitter release in the central nervous system, reducing nausea, pain perception, and appetite dysregulation, while CB2 activation contributes to anti‑inflammatory and immunomodulatory effects. The combined activity produces anti‑emetic, analgesic, and appetite‑stimulating outcomes.

Side Effects

  • Adverse reactions may occur with inhaled cannabinoid therapy.\n\nCommon Side Effects:\n- Dizziness\n- Dry mouth\n- Fatigue\n- Nausea\n- Impaired coordination\n- Mood changes\n\nSerious or Rare Side Effects:\n- Psychosis or severe anxiety\n- Marked hypotension\n- Respiratory depression\n- Allergic reactions (rash, angioedema)\n- Worsening of seizure activity\n- Cardiovascular events such as arrhythmia

Precautions & Warnings

  • Use of Midnight/Tikun requires careful clinical consideration.\n\n- Hepatic function: assess before initiating therapy.\n- Psychiatric monitoring: watch for anxiety, depression, or psychotic symptoms.\n- CNS depressants: avoid concurrent use due to additive sedation.\n- Cardiovascular disease: use cautiously in patients with hypotension or arrhythmias.\n- Pregnancy and breastfeeding: safety unknown; avoid unless benefits clearly outweigh risks.\n- Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

  • Midnight/Tikun can interact with several drug classes.\n\nMajor Interactions (Avoid):\n- CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations.\n- Central nervous system depressants (e.g., benzodiazepines): additive sedation risk.\n- Anticoagulants (e.g., warfarin): potential for increased bleeding.\n\nModerate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect.\n- Antihypertensives: possible enhancement of hypotensive response.\n- Other cannabinoids: unpredictable pharmacodynamic synergy or antagonism.

Frequently Asked Questions

Midnight/Tikun is prescribed for chemotherapy‑induced nausea and vomiting, appetite stimulation in patients with AIDS‑related cachexia, certain seizure disorders, and chronic pain that has not responded adequately to standard therapies.

Both dronabinol and cannabidiol act as partial agonists at cannabinoid receptors CB1 and CB2. CB1 activation modulates neurotransmitter release in the brain, reducing nausea and pain, while CB2 activation provides anti‑inflammatory and immune‑modulating effects, together supporting appetite and symptom control.

The specific dose and frequency of Midnight/Tikun are determined by the prescribing clinician based on the individual patient's condition, response, and tolerability. No fixed regimen is provided in public literature.

Safety data for dronabinol and cannabidiol during pregnancy or lactation are limited. The product should be avoided unless the potential therapeutic benefit justifies the potential risk to the fetus or infant, and only under close medical supervision.

To request Midnight/Tikun, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Midnight/Tikun offers a cannabinoid‑based mechanism distinct from traditional anti‑emetics such as serotonin antagonists or opioids for pain. Its dual action on CB1 and CB2 receptors can benefit patients who have inadequate response or intolerable side effects from standard therapies, though individual response varies.

Midnight/Tikun should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product protected from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability.

Midnight/Tikun is supplied as an inhalation product. The patient inhales the prescribed dose using the designated device, following the healthcare professional’s instructions for technique, frequency, and duration of each inhalation session.

Serious risks include the potential for psychotic episodes, severe hypotension, respiratory depression, allergic reactions such as angioedema, and worsening of seizure activity. Patients should be monitored closely for these events, especially during treatment initiation or dose adjustments.

Midnight/Tikun is contraindicated in patients with known hypersensitivity to dronabinol, cannabidiol, or any excipients, as well as in individuals with uncontrolled cardiovascular disease, severe psychiatric disorders, or those taking prohibited major interacting medications without appropriate medical oversight.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Dronabinol, Cannabidiol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT